By Kelly A. Briganti, Editorial Director, G2 Intelligence
A federal district court has weighed in on the meaning of "identified" for purposes of determining when Medicare and Medicaid overpayments must be returned to avoid violating the False Claims Act. That court resolved the debate about when the Affordable Care Act's 60-day deadline for returning overpayments begins to run, explaining the deadline is triggered when providers are on notice that they may have received overpayments—not after they've determined with certainty the…
Read more...
Leverage Your Laboratory Data into Value with Orchard's School of Medical Analytics
Orchard School of Medical Analytics, a division of Orchard Software, will educate pathologists and healthcare leaders in the use of advanced analytics to improve patient care and reduce costs. The four-day course will provide pathologists and laboratory leaders with an opportunity to prepare for the future by studying proven strategies in which laboratory data compiled with billing, pharmacy, and other clinical data has been successfully used to save money and improve patient care.
The course will be led by Dr. Brad Brimhall, who is an expert in medical analytics and data warehousing. The course will include instruction on healthcare organizational structures, cost-accounting, accounting for quality, medical data and databases, and a review of analytics projects and presentation skills.
In the new value-focused healthcare paradigm, the need for laboratory data is more apparent than ever. Not only can laboratory data be used to aid in diagnosis and treatment plans, it can be combined with other data and used to greatly reduce overall organization-wide costs in areas far beyond the lab. The value of the clinical data that the laboratory produces is invaluable, yet its potential to drive change that leads to positive patient outcomes and cost savings is worth much more.
For more information on the Orchard School of Medical Analytics, contact Orchard at (800) 856-1948.
By Ron Shinkman, Editor, Laboratory Industry Report
San Diego-based Biocept will collaborate with the University of California at Irvine to study differences in biomarkers in blood-based specimens versus invasive tissue samples.
The intent, officials say, is to be able to more extensively use liquid biopsies to help connect patients with metastatic cancer to targeted therapies.
Liquid biopsies are being pushed by…
Read more...
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies
Unmanned Aerial Systems (UAS or drones) could potentially be used to transport clinical laboratory specimens. Transportation of laboratory specimens via small UASs does not affect the accuracy of routine chemistry, hematology, and coagulation test results, according to a study published online July 29 in…
Read more...
By Kelly A. Briganti, Editorial Director, G2 Intelligence
The U.S. Food and Drug Administration (FDA) has announced the development of precisionFDA, "an informatics community and supporting platform" to assist efforts to maximize the potential of genetic information. The FDA plans to launch the platform in December via a beta release and describes it as a "crowd-sourced, cloud-based platform to advance the science needed to develop the necessary standards" for…
Read more...
|
